Looks like the Medical Community is finally catching up with the patient community; i.e.:
"I think the key result of this study is that sequencing testosterone and then anti-testosterone therapy, in this case enzalutamide, seems to be the ideal way [to modify the adaptive process]," Denmeade told MedPage Today. "A tumor seems to be sensitive and then adapts and becomes insensitive, so you switch treatments."
* * *
"We're at a point where we're trying to understand the best way to use this treatment," said Denmeade. "We're still working on how to incorporate testosterone into the treatment paradigm. We think it has the potential to augment and extend the response."
Always before T was seen as "bad for Pca" and now, it is good for treatment. I think getting the ideal time for administration and figuring out who benefits will be key to developing this as a therapeutic regimen. I look for some genetic testing to start being part of the protocols in an effort to find out which genetic mutations do the best on this treatment. DeMeade and Sartor are both doing BAT and whether some of the chemos will be tried next with BAT is any one's guess. Good find...
Next thing we will hear is that the docs are going back to estrogen as a mainstay to treat PCa. Which would once again be the Medical Community catching up with the patient community.
That patients have found the need to look outside SOC for treatment options says a lot about how slow the research has been to provide lasting treatment results, especially for those with advanced disease. Lots of n=1 self-directed "clinical trials" going on out here in the real world, where we live or die based on the decisions made by us and/or our docs. I know, as I am one of them doing one.
Keep the science coming, Fish, as we need all we can get, as fast as we can get it. In the meantime, Keep It Safe & Well - K9
Another good article... Thanks for sharing....The use of estrogen to control PCa has come under further investigation and one posting on another forum from ronronHU:
Almost 3 years of control using estrogen... I do wonder if people could alternate estrogen and Lupron and get longer control without castrate resistance. The science has come great distances in 10 to 15 years... I watch ARV-110, an AR Degrader, with great interest....Thanks for the reply...
Thailand is apparently well known for its "ladyboys", so, as ronron indicates in his post, he is in good hands, so to speak, by being located there. I think there are quite a few other posters at that "other" forum who have used Estrogen patches and/or gels. Many believe it is the 'balance' of sex hormones that needs to be monitored. I'll have to do a search for the ARV-110 & AR Degrader, as they are new to me.
Here is a recent press release on the PROTAC/ AR Degrader known as ARV-110. The results are impressive being used on a heavily pretreated population of PCa patients. It works well against T878 or H875 mutations, as well as wild AR mutations. It is what I call the first of the 3rd generation AR drugs.
It is interesting that some get great benefit and others do not. I do wonder if it is based on mutations or timing of meds.... Another point of interest is how well tolerated it is based on the huge swings of T enrichment and depletion and how it effects the physical and mental well being of those that went through the treatment.
Here is another article I found-- an interview of DeMeade and how he thinks it works and where it is going... the COMBAT trial using BAT plus a CPI seems quite promising...
At this point, I have an interest only from a scholastic point of view....I do not need BAT at this time and if I ever do, then there will be much more information then.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Phase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer